Watch for Sotyktu, a New Oral Med for Psoriasis
March 2023
Sotyktu (deucravacitinib) will be a new oral option for adults with psoriasis.
It’s the first in a new class of meds that blocks a protein linked to inflammation in psoriasis.
Once-daily Sotyktu appears to be more effective than twice-daily oral Otezla (apremilast). But these meds cost more than other oral options for psoriasis (methotrexate, acitretin, etc).
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote